This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (40)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Elizabeth H. Corder, PhD; Ann M. Saunders, PhD; Warren J. Strittmatter, MD; Don E. Schmechel, MD; P. C. Gaskell, Jr, PA-C; A. D. Roses, MD; M. A. Pericak-Vance, PhD
Duke University Medical Center Durham, NC

G. W. Small, MD
University of California, Los Angeles

J. L. Haines, PhD
Harvard University Boston, Mass

JAMA. 1995;273(5):373-374.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Recently, Dr Payami and colleagues proposed a difference in Alzheimer's disease (AD) risk between men and women who have one copy of the apolipoprotein E (apo E) E4 allele.¹ Specifically, they suggested that men with no or one copy of E4 (the E2/E2, E2/E3, E3/E3, E2/E4, and E3/E4 genotypes) have a decreased risk of AD compared with men with two copies (the E4/E4 genotype), while women with no copy of E4 have a decreased risk of AD compared with those with one or two copies. Our studies do not suggest this sex-specific pattern of risk.^2,3 We find instead that risk of AD, both familial and sporadic (ie, no family history), increases with the number of E4 alleles in men and women.

The E4 gene dose effect was initially found in 234 members of 42 AD families older than 60 years and can be seen when . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West), and Margaret A. Winker, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?